

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Hanx Biopharmaceuticals (Wuhan) Co., Ltd.**

### **翰思艾泰生物醫藥科技（武漢）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3378)**

- (1) RE-DESIGNATION FROM NON-EXECUTIVE DIRECTOR TO EXECUTIVE DIRECTOR;**
- (2) CHANGE IN THE COMPOSITION OF THE BOARD COMMITTEE;**
- (3) RESIGNATION OF JOINT COMPANY SECRETARY, CHIEF FINANCIAL OFFICER, SECRETARY OF THE BOARD AND VICE GENERAL MANAGER; AND**
- (4) APPOINTMENT OF CHIEF FINANCIAL OFFICER AND SECRETARY OF THE BOARD**

#### **RE-DESIGNATION FROM NON-EXECUTIVE DIRECTOR TO EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “**Company**”, together with its subsidiaries, as the “**Group**”) hereby announces that, due to work adjustment, Ms. Xiao Jieyu (“**Ms. Xiao**”) has been re-designated from a non-executive Director to an executive Director with effect from 8 February 2026.

The biographical details of Ms. Xiao are set out as follows:

Ms. Xiao, aged 43, graduated from the Huazhong Agricultural University (華中農業大學) with a Bachelor’s Degree in Plant Protection in June 2005. She further obtained a Master’s Degree in Pharmacology from Shanghai Institute of Pharmaceutical Industry (上海醫藥工業研究院) in June 2008. She received the Certification of Fund Practice Qualification (基金業從業證書) from the Asset Management Association of China (中國證券投資基金業協會) in June 2017.

Ms. Xiao joined the Group and was appointed as a Director on 1 March 2024. She was redesignated as a non-executive Director on 22 August 2024. Prior to joining our Company, she worked as a senior investment manager at Wuhan Optics Valley Venture Capital Private Equity Fund Management Co., Ltd. (武漢光谷創投私募基金管理有限公司) from June 2012 to June 2015 and was responsible for investment and corporate finance works. From February 2016 to October 2016, she worked as a deputy manager at Hubei Branch of Huayuan Securities Co., Ltd. (華源證券股份有限公司) (formerly known as Jiuzhou Securities Co., Ltd. (九州證券股份有限公司)) and was responsible for investment banking, investment and financing works. From November 2016 to October 2019, she worked as an investment director at Hubei Changjiang Hezhi Equity Investment Fund Management Co., Ltd. (湖北省長江合志股權投資基金管理股份有限公司). From May 2021 to August 2025, she worked as a deputy general manager of Wuhan East Lake High Tech Investment Management Co., Ltd. (武漢東湖高新股權投資管理有限公司) and was responsible for investment and financing related matters. From July 2021 to July 2022, she worked as a director of Pugao Medical Technology (Nanjing) Co., Ltd. (譜高醫療科技(南京)有限公司) and was responsible for providing guidance on investment strategies and corporate governance. Furthermore, she has also been acting as a director of Wuhan Bintong Biotechnology Co., Ltd. (武漢濱通生物技術有限公司), responsible for providing guidance on investment strategies and corporate governance since June 2021, a director of Chengdu Jinweike Biotechnology Co., Ltd. (成都金唯科生技有限公司), responsible for providing guidance on investment strategies and corporate governance since January 2022, as well as a director of Wuhan Bank-Biotechnology Co., Ltd. (武漢班科生物技術有限公司), responsible for providing guidance on investment strategies and corporate governance since August 2022, respectively.

Ms. Xiao will enter into a service contract (the “**Service Contract**”) with the Company for a term commencing from 8 February 2026 until the expiration of the term of office of the current Board. Ms. Xiao will not be entitled to receive any director’s fee. Save as the remuneration to Ms. Xiao as chief financial officer and secretary of the Board, Ms. Xiao will not receive any remuneration from the Company. The letter of appointment entered into between Ms. Xiao and the Company on 1 March 2024 in relation to her appointment as a non-executive Director will be terminated following the effective date of the Service Contract.

As at the date of this announcement, Ms. Xiao holds 11,100 H shares of the Company as a beneficial owner, representing 0.0081% of the total issued share capital of the Company.

Ms. Xiao has confirmed that, save as disclosed in this announcement, she (i) has not held any directorships in the last three years in any public companies whose securities are listed on any securities market in Hong Kong or overseas; (ii) does not hold any other positions in the Company and its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) of the Company; and (iv) does not hold any interest in any shares, underlying shares or debenture of the Company and/or its associated corporation within the meaning of Part XV of Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, there is no other information in relation to Ms. Xiao that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and no other matters that needs to be brought to the attention of the shareholders of the Company.

#### **CHANGE IN THE COMPOSITION OF THE BOARD COMMITTEE**

Following the re-designation of Ms. Xiao as an executive Director comes into effect, she will cease to be a member of the Audit Committee with effect from 8 February 2026.

Dr. Zhang Qiongguang, an independent non-executive Director, has been appointed as a member of the Audit Committee with effect from 8 February 2026.

#### **RESIGNATION OF JOINT COMPANY SECRETARY, CHIEF FINANCIAL OFFICER, SECRETARY OF THE BOARD AND VICE GENERAL MANAGER**

The Board further announces that, Mr. Zhang Hui (“**Mr. Zhang**”) has resigned as the joint company secretary, vice general manager, chief financial officer and secretary of the Board of the Company effective from 8 February 2026 to pursue his other personal and career developments.

Mr. Zhang confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company.

Mr. Li Kin Wai (“**Mr. Li**”), another joint company secretary of the Company, will continue to act as the company secretary of the Company. The Company has designated Ms. Xiao as the main contact person at its headquarters who will be responsible maintaining day-to-day communication with Mr. Li.

Mr. Li is currently a Senior Manager of Corporate Services of Tricor Services Limited. He possesses over 10 years of extensive experience in the corporate secretarial profession. He is familiar with the Hong Kong Stock Exchange Listing Rules, the Companies Ordinance as well as compliance work for offshore companies. He specializes in providing corporate secretarial, corporate governance and compliance services to Hong Kong listed companies as well as multinational, private and offshore companies.

Mr. Li is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhang for his contribution to the Company during his tenure.

### **APPOINTMENT OF CHIEF FINANCIAL OFFICER AND SECRETARY OF THE BOARD**

The Board further announces that Ms. Xiao has been appointed as the chief financial officer and secretary of the Board of the Company with effect from 8 February 2026. Pursuant to the Service Contract, Ms. Xiao will receive a basic remuneration of RMB750,000 per annum, and a discretionary bonus which will be determined by the Board from time to time with reference to, among other things, the performance of Ms. Xiao and the overall performance of the Group.

The Board would like to take this opportunity to congratulate Ms. Xiao on her new position with the Company.

By order of the Board  
**Hanx Biopharmaceuticals (Wuhan) Co., Ltd.**  
**Dr. ZHANG Faming**  
*Chairman and Executive Director*

Hong Kong, 4 February 2026

*As at the date of this announcement, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian and Ms. Xiao Jieyu as non-executive Directors; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.*